Elsevier

Urology

Volume 42, Issue 2, August 1993, Pages 119-130
Urology

Rapid communication
Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III eortc trial (30853)

https://doi.org/10.1016/0090-4295(93)90634-MGet rights and content

Abstract

Maximal androgen blockade (MAB), the eradication of the effects of adrenal androgens on prostate cancer cells after castration, has been used with differing success in the treatment of prostatic carcinoma. The aim of this randomized phase III study was to compare the efficacy and side effects of bilateral orchiectomy versus a combination of a luteinizing hormone-releasing hormone agonist (LHRH-A) depot formulation, goserelin acetate (3.6 mg s.c. once every four weeks), and flutamide (250 mg three times daily), in patients with metastatic cancer. Treatment usually continued until disease progression (or for a minimum of three months). Efficacy was assessed by response, time to disease progression, and duration of survival. Clinical evaluations, standard laboratory tests, and imaging examinations were carried out regularly. A total of 327 patients were entered in this study. There was a difference in response only for prostatic acid phosphatase (PAP) with a more frequent decrease of the serum values to normal in the serum in patients assigned to MAB treatment. The MAB treatment, however, proved significantly better for time to subjective progression, time to objective progression, time to first (subjective and objective) progression, and duration of survival. The most frequent side effects for both treatments included hot flushes and gynecomastia. In conclusion, significant time to progression and survival benefits are achieved by adding flutamide to an LHRH-A-regimen, probably improving the quality of life of patients with metastatic cancer.

References (16)

  • F.M.J. Debruyne et al.

    Long-term therapy with a depot luteinizing hormone-releasing hormone analogue (Zoladex) in patients with advanced prostatic carcinoma

    J Urol

    (1988)
  • C. Huggins et al.

    Bilateral adrenalectomy in prostatic cancer. Clinical features and urinary excretion of 17ketosteroids and estrogen

    Ann Surg

    (1945)
  • T. Bhanalaph et al.

    Current status of bilateral adrenalectomy for advanced prostatic cancer

    Ann Surg

    (1974)
  • L. Denis

    The medical management of prostate cancer, 11. European School of Oncology Monograph Series

  • U. Bracci

    Antiandrogens in the treatment of prostatic cancer

    Eur Urol

    (1979)
  • M.R.G. Robinson

    EORTC protocol 30805: A phase-III trial comparing orchidectomy versus orchidectomy and cyproterone acetate and low-dose stilboestrol in the management of metastatic carcinoma of the prostate

  • Klijn JGM, de Voogt HJ, Studer UE, Schröder FH, Sylvester R, De Paux M, and Members of EORTC-GU Group: Short-term...
  • F. Labrie et al.

    A complete androgen blockade for the treatment of prostate cancer

There are more references available in the full text version of this article.

Cited by (286)

  • Accessory Sex Glands in the Male

    2015, Knobil and Neill's Physiology of Reproduction: Two-Volume Set
View all citing articles on Scopus
View full text